Alpha-arylethylpiperazine derivatives as neurokinin antagonists

The invention relates to new alpha -arylethylpiperazine derivatives, which are useful as neurokinin receptor antagonists (NK1antagonists). It also relates to processes for the preparation of said alpha -arylethylpiperazine derivatives, to their use for the prevention and/or treatment of a condition...

Full description

Saved in:
Bibliographic Details
Main Authors MICHEL NEUWELS, FLORENCE MOUREAU, FRANCOISE STIERNET, MARIE-AGNES LASSOIE, THOMAS RYCKMANS, SOLO GOLDSTEIN, CHRISTOPHE GENICOT, THIERRY TAVERNE, JEAN-PIERRE HENICHART
Format Patent
LanguageEnglish
Published 03.07.2001
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The invention relates to new alpha -arylethylpiperazine derivatives, which are useful as neurokinin receptor antagonists (NK1antagonists). It also relates to processes for the preparation of said alpha -arylethylpiperazine derivatives, to their use for the prevention and/or treatment of a condition associated with pathogical levels of substance P in a patient and to pharmaceutical compositions containing them.
AbstractList The invention relates to new alpha -arylethylpiperazine derivatives, which are useful as neurokinin receptor antagonists (NK1antagonists). It also relates to processes for the preparation of said alpha -arylethylpiperazine derivatives, to their use for the prevention and/or treatment of a condition associated with pathogical levels of substance P in a patient and to pharmaceutical compositions containing them.
Author SOLO GOLDSTEIN
THOMAS RYCKMANS
JEAN-PIERRE HENICHART
MICHEL NEUWELS
FRANCOISE STIERNET
MARIE-AGNES LASSOIE
FLORENCE MOUREAU
CHRISTOPHE GENICOT
THIERRY TAVERNE
Author_xml – fullname: MICHEL NEUWELS
– fullname: FLORENCE MOUREAU
– fullname: FRANCOISE STIERNET
– fullname: MARIE-AGNES LASSOIE
– fullname: THOMAS RYCKMANS
– fullname: SOLO GOLDSTEIN
– fullname: CHRISTOPHE GENICOT
– fullname: THIERRY TAVERNE
– fullname: JEAN-PIERRE HENICHART
BookMark eNqFyj0KwkAQBtAttPDvDO4FApqAlrKI4gG0DoN-JoPL7LIzBuLpbeytXvPmbiJJMHOHEHNPFZUxwvoxZs4o9GGBf6DwQMYD1JN6wbukFwuLJzHqkrCaLt30SVGx-rlw6_PperxUyKmFZrpDYG241bt9U2-2ofk_vnINMyM
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 7
ExternalDocumentID AU2673201A
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2673201A3
IEDL.DBID EVB
IngestDate Fri Jul 19 15:21:08 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2673201A3
Notes Application Number: AU2673201
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010703&DB=EPODOC&CC=AU&NR=2673201A
ParticipantIDs epo_espacenet_AU2673201A
PublicationCentury 2000
PublicationDate 20010703
PublicationDateYYYYMMDD 2001-07-03
PublicationDate_xml – month: 07
  year: 2001
  text: 20010703
  day: 03
PublicationDecade 2000
PublicationYear 2001
RelatedCompanies U C B, S.A
RelatedCompanies_xml – name: U C B, S.A
Score 2.5396333
Snippet The invention relates to new alpha -arylethylpiperazine derivatives, which are useful as neurokinin receptor antagonists (NK1antagonists). It also relates to...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Alpha-arylethylpiperazine derivatives as neurokinin antagonists
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20010703&DB=EPODOC&locale=&CC=AU&NR=2673201A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEB5qFfWmVanvHCS3xbzTHEJJ86AIfSCt9Fby2NiiJCGJSv-9s2ujXnpbdmGZHebb2dmd-RbgQdZoKilJRFIrNYhmmiHpxZFOkpDfQZqGxZ8LRmNjONeeFvqiBaumFobzhH5xckREVIx4r_l-XfxdYnk8t7J6jNbYlfeDme2JTXQsMwsWvYHtTyfexBVdFyNJcfxsK4apoq9z9mAfD9EmS_7yXwasJqX471CCEziY4lxZfQotmnXgyG3-XevA4Wj73I3NLfKqM-g7rCiWhOUGFb3avBfrgpacGlpI0Ig-OX93JYSVwBkq39i_DwJqLXzNGTdudQ73gT9zhwQlWf4ueunMG5HVC2hneUa7ICSxzlAWJ5oRa-iLLapIPYZCqsaSJsuX0N01y9XuoWs4_smsMomk3kC7Lj_oLbraOrrjWvoGr86EQw
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dT8IwEL8gGvFNUYOf7MHsrXFjX_CwENhYUNkgBgxvZB-dEM22sKnhv_damfrCW9Mml-ulv17bu_sV4E5WaSy1ooDEnVgnqmH4pB0GGol8_gZp6B0eLnA9fThTH-favALLshaG84R-cXJERFSIeC_4fp39PWLZPLcyvw9W2JV2nalpi-XtWGYrWLT75mAytseWaFl4kxS9Z7OlGwr6ut4e7OMBu81Y9gcvfVaTkv13KM4xHExQVlKcQIUmdahZ5b9rdTh0t-FubG6Rl59Ct8eKYom_3qChl5v3bJXRNaeGFiJcRJ-cvzsX_FzgDJVv7N8HAa3mv6aMGzc_g6YzmFpDgposfie96M1KlZVzqCZpQhsgRKHGUBZGqh6q6Is7tCW1GQqpEkqqLF9AY5eUy91DTagNp-5oMXrwnq7g6CfLyiCScg3VYv1Bb9DtFsEtt9g3C7mHMw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Alpha-arylethylpiperazine+derivatives+as+neurokinin+antagonists&rft.inventor=MICHEL+NEUWELS&rft.inventor=FLORENCE+MOUREAU&rft.inventor=FRANCOISE+STIERNET&rft.inventor=MARIE-AGNES+LASSOIE&rft.inventor=THOMAS+RYCKMANS&rft.inventor=SOLO+GOLDSTEIN&rft.inventor=CHRISTOPHE+GENICOT&rft.inventor=THIERRY+TAVERNE&rft.inventor=JEAN-PIERRE+HENICHART&rft.date=2001-07-03&rft.externalDBID=A&rft.externalDocID=AU2673201A